Most supplier content about a botanical's regulatory history is written to make the history go away. This is not that. The honest position on manjistha involves a fact that is inconvenient to state and worse to omit, and a buyer is better served by having it early than by discovering it in the middle of a safety assessment.
What Happened in Europe
Rubia tinctorum — European dyer's madder — has a long history as the continent's principal red dye plant and, in herbal practice, as a traditional remedy.
That changed. Regulatory action was taken in Europe against madder root preparations on genotoxicity grounds, associated with the anthraquinone lucidin, which was found to be mutagenic in testing. Preparations of R. tinctorum root were withdrawn from the market as a result.
This is a genuine and consequential regulatory event affecting a plant that had centuries of traditional use behind it. Long use did not settle the question — testing did.
What This Does and Does Not Mean for Manjistha
Precision matters here, in both directions.
What it does not mean: manjistha is Rubia cordifolia, a distinct species with its own long documented history of use in India. The European action concerned R. tinctorum. It does not automatically transfer to a different species, and it would be wrong to present it as though it did.
What it does mean: three facts sit alongside each other and deserve to be handled rather than skipped past.
- The genus shares an anthraquinone chemistry. Individual constituents vary between species, but the class is common;
- R. tinctorum is cheap and available, and once dried and milled into a red root powder it is not readily distinguishable from R. cordifolia;
- The constituent class in question is the commercially defining one — it is what makes these plants red and what makes them useful.
Together those three points produce a straightforward procurement conclusion: species must be verified analytically, and the anthraquinone profile should be documented rather than left unmentioned. Not because manjistha is presumed unsafe, but because the alternative is relying on an absence of information as though it were an assurance.
Does R. cordifolia Contain Lucidin?
The question every serious buyer asks, and one we answer carefully rather than conveniently.
Anthraquinone composition within Rubia varies by species, by growing conditions and by analytical method. Rather than offer a blanket assurance, our approach is to report the anthraquinone profile of each batch by HPLC, so your assessment rests on data from the material you are actually buying, and to arrange specific anthraquinone testing where a regulatory review calls for it.
What we will not do is tell a buyer the question does not arise. It plainly does arise, and a supplier who waves it away has told you something about how they handle inconvenient questions generally.
Topical and Oral Are Different Questions
This distinction carries real weight and is frequently collapsed.
| Topical / cosmetic | Oral / ingested | |
|---|---|---|
| Exposure route | Dermal | Systemic via ingestion |
| Regulatory framework | Cosmetic regulation | Food supplement / traditional medicine |
| Safety assessment | Cosmetic safety assessment | Anthraquinone question is central |
| Commercial share | The great majority of manjistha | Smaller |
The great majority of commercial manjistha goes into cosmetic formulation, where the assessment framework is different in kind from that for an ingested product. Buyers formulating oral products should place the anthraquinone question squarely inside their own safety and regulatory review, with species verification and profile data in hand.
The EU Adds a Second Question
For EU-bound oral products there is also novel food status to confirm for a concentrated extract. A traditional preparation and a modern standardised extract are not automatically treated alike, and that determination depends on your specification, concentration and intended use.
It belongs with your regulatory reviewer. We will supply the specification detail and process documentation the review needs. Our guide to EU import requirements covers the wider framework.
Why We Put This on a Product Page
A fair question, since it is not obviously good salesmanship.
The reason is that this information reaches a buyer eventually. It reaches them through a regulatory reviewer, a retailer's technical audit, or a customer question — and if it arrives after they have formulated, sourced and printed packaging, it arrives as a crisis rather than as a consideration.
A supplier who omits it has not protected the customer from anything. They have simply arranged for the customer to find out at a worse moment, and taught them something about the supplier in the process.
Our position: manjistha is a legitimate, long-used botanical with a substantial and well-established cosmetic market. It sits in a genus with a regulatory history. Both statements are true, and a buyer is better equipped holding both than holding only the first.
What We Do
- Species verified by HPLC fingerprint against authentic R. cordifolia reference, R. tinctorum excluded — every batch;
- Anthraquinone profile reported per batch;
- Intended application recorded — topical or oral — with the documentation set matched to it;
- Specific anthraquinone testing arranged where a regulatory review requires it.
Talk to us about manjistha, and tell us the application — it changes what you should be asking for.
Source Species-Verified Manjistha Extract from India
Rubia cordifolia root extract · species verified by HPLC, R. tinctorum excluded · anthraquinone profile reported · topical and oral documentation · CoA-backed · samples for qualified buyers